Compare GCO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | KALA |
|---|---|---|
| Founded | 1924 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.0M | 319.6M |
| IPO Year | 1994 | 2017 |
| Metric | GCO | KALA |
|---|---|---|
| Price | $27.81 | $0.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $33.00 | $31.50 |
| AVG Volume (30 Days) | 212.0K | ★ 7.6M |
| Earning Date | 03-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | 41.50 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $2,606,898,000.00 | N/A |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $22.38 | ★ N/A |
| Revenue Growth | ★ 13.71 | N/A |
| 52 Week Low | $16.19 | $0.16 |
| 52 Week High | $38.95 | $20.58 |
| Indicator | GCO | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 24.66 |
| Support Level | $27.02 | N/A |
| Resistance Level | $29.79 | $0.72 |
| Average True Range (ATR) | 1.30 | 0.03 |
| MACD | 0.41 | -0.00 |
| Stochastic Oscillator | 77.18 | 2.17 |
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.